Clinical Trial: Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subject
Brief Summary: An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
Detailed Summary:
Sponsor: UCB Pharma
Current Primary Outcome: Around 4 years of Safety assessment of levetiracetam via Adverse Events reporting,
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: UCB Pharma
Dates:
Date Received: September 6, 2005
Date Started: August 2005
Date Completion:
Last Updated: December 5, 2013
Last Verified: September 2009